Valeritas Holdings Inc (NASDAQ:VLRX) – Equities research analysts at Oppenheimer upped their Q2 2019 earnings per share estimates for Valeritas in a report released on Monday, July 8th. Oppenheimer analyst S. Lichtman now anticipates that the company will post earnings per share of ($2.90) for the quarter, up from their prior estimate of ($3.00). Oppenheimer currently has a “Outperform” rating and a $12.00 price target on the stock. Oppenheimer also issued estimates for Valeritas’ Q3 2019 earnings at ($2.66) EPS, Q4 2019 earnings at ($2.53) EPS, FY2019 earnings at ($11.14) EPS and FY2020 earnings at ($9.37) EPS.

Valeritas (NASDAQ:VLRX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15). The company had revenue of $6.40 million during the quarter, compared to the consensus estimate of $6.20 million. Valeritas had a negative return on equity of 1,757.04% and a negative net margin of 183.53%.

Separately, ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd.

NASDAQ VLRX opened at $3.12 on Thursday. The firm has a market cap of $19.91 million, a P/E ratio of -0.09 and a beta of 1.77. The company has a current ratio of 3.32, a quick ratio of 2.81 and a debt-to-equity ratio of 29.19. Valeritas has a 12 month low of $2.10 and a 12 month high of $34.00. The firm has a 50 day moving average of $3.02.

In related news, major shareholder Armistice Capital Master Fund acquired 226,000 shares of the business’s stock in a transaction dated Tuesday, May 21st. The stock was bought at an average price of $0.66 per share, with a total value of $149,160.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. In the last three months, insiders bought 350,000 shares of company stock valued at $234,640. 1.02% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in VLRX. CVI Holdings LLC acquired a new stake in Valeritas during the 4th quarter valued at $832,000. Millennium Management LLC acquired a new stake in Valeritas during the 4th quarter valued at $165,000. Northern Trust Corp lifted its holdings in Valeritas by 855.4% during the 4th quarter. Northern Trust Corp now owns 185,469 shares of the company’s stock valued at $60,000 after purchasing an additional 166,057 shares during the last quarter. Weiss Multi Strategy Advisers LLC acquired a new stake in Valeritas during the 4th quarter valued at $41,000. Finally, Geode Capital Management LLC lifted its holdings in Valeritas by 138.0% during the 4th quarter. Geode Capital Management LLC now owns 186,971 shares of the company’s stock valued at $60,000 after purchasing an additional 108,416 shares during the last quarter.

Valeritas Company Profile

Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization.

Read More: Trading Stocks – What are percentage gainers?

Earnings History and Estimates for Valeritas (NASDAQ:VLRX)

Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.